Skip to main content
Monday, November 16, 2026Nov 16

Money promised to combat US overdose crisis sits unused

Jill Cichowicz, an advocate for opioid addiction treatment, displays a photo of her and her brother, Scott Zebnwski, who died of an opioid overdose at age 38, in her home in Midlothian, Va., Tuesday, Nov. 24, 2020. (AP Photo/Steve Helber)
Jill Cichowicz, an advocate for opioid addiction treatment, displays a photo of her and her brother, Scott Zebnwski, who died of an opioid overdose at age 38, in her home in Midlothian, Va., Tuesday, Nov. 24, 2020. (AP Photo/Steve Helber)

When it filed for bankruptcy last year, Purdue Pharma agreed to an innovative plan: It would make $200 million available immediately to help those those harmed by its signature painkiller, OxyContin, and ease the effects of the opioid crisis.

More than a year later, with the crisis worsening, not a penny has been spent.

“The money is just sitting in Purdue’s bank account collecting dust,” said Ed Neiger, a lawyer representing opioid victims. “It’s a travesty of epic proportions.”

It’s not Purdue that is holding up the money. Instead, it’s lawyers representing the wide range of entities suing the company who cannot agree how best to use it. The main disagreement is between nearly 3,000 local governments and advocates for those hurt by opioids.

Advocates want the money funneled mostly to local nonprofits that provide emergency services to people with addictions. State attorneys general say doing so would dilute the money so much it would not be effective. Because Purdue is undergoing the long process of distributing its assets, the states also see the prospect of distributing billions of dollars over time as more important than the $200 million.